Phase 4 Trial, Dexmedetomidine, Myocardial Protection, PCI
Summary
A Phase 4 clinical trial (NCT07549282) is evaluating preoperative intranasal dexmedetomidine (100 μg) versus placebo for reducing perioperative myocardial injury and myocardial infarction in patients undergoing elective percutaneous coronary intervention (PCI). Participants receive the study drug or normal saline 15 minutes before PCI and are monitored for up to 30 days post-procedure with cardiac troponin blood tests before and after the procedure. The trial is registered on ClinicalTrials.gov under NIH oversight.
“Researchers will compare intranasal dexmedetomidine to a placebo (a look-alike substance that contains no drug) to see if intranasal dexmedetomidine works to protect the heart during PCI.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A Phase 4 clinical trial (NCT07549282) has been registered to study whether preoperative intranasal dexmedetomidine (100 μg) reduces perioperative myocardial injury and myocardial infarction in patients undergoing elective percutaneous coronary intervention (PCI). Participants will be randomized to receive intranasal dexmedetomidine or placebo 15 minutes before the procedure, with blood tests measuring cardiac troponin levels and 30-day follow-up for heart-related events or side effects. The trial expands research into dexmedetomidine's cardioprotective properties beyond its established ICU sedation indication.
Healthcare providers and patients considering PCI procedures should note this is an investigational protocol requiring institutional review board approval and informed consent. The trial may inform future off-label use applications if efficacy is demonstrated.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Use Dexmedetomidine To Protect Myocardial Injury Evaluation
Phase 4 NCT07549282 Kind: PHASE4 Apr 24, 2026
Abstract
The goal of this clinical trial is to learn if preoperative intranasal dexmedetomidine works to reduce perioperative myocardial injury and myocardial infarction in patients undergoing elective percutaneous coronary intervention (PCI). It will also learn about the safety of intranasal dexmedetomidine. The main questions it aims to answer are:
Does preoperative intranasal dexmedetomidine lower the incidence of perioperative myocardial injury and myocardial infarction after PCI? Does intranasal dexmedetomidine cause safety concerns in patients undergoing PCI? Researchers will compare intranasal dexmedetomidine to a placebo (a look-alike substance that contains no drug) to see if intranasal dexmedetomidine works to protect the heart during PCI.
Participants will:
Receive either intranasal dexmedetomidine (100 μg) or a placebo (normal saline) 15 minutes before the PCI procedure Undergo blood tests to measure cardiac troponin levels before and after the procedure Be followed for up to 30 days after the procedure to record any heart-related events or side effects
Conditions: Coronary Heart Disease, Myocardial Injury, Myocardial Infarction, Dexmedetomidine
Interventions: Intranasal Dexmedetomidine, Normal saline
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.